Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC-001 and QS-21 Adjuvant in Early Alzheimer's Disease
NCT01227564Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2011
- Primary completion
- Feb 2014
- Modality
- Antibody Conjugates, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of vanutide cridificar in Alzheimer's disease (AD), sponsored by Pfizer. Started Feb 2011; status: completed.
02
Drugs
vanutide cridificar
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01227564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01227564.